Ken Griffin Xoma Corp Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$23.1 - $29.85 $20,790 - $26,865	-900 Reduced 90.0%	100 $2,000
Q2 2024 Aug 14, 2024	SELL	$22.31 - $26.7 $203,021 - $242,970	-9,100 Reduced 90.1%	1,000 $23,000
Q4 2023 Feb 14, 2024	SELL	$13.82 - $19.13 $105,032 - $145,388	-7,600 Reduced 42.94%	10,100 $186,000
Q3 2023 Nov 14, 2023	BUY	$14.02 - $17.71 $88,326 - $111,573	6,300 Added 55.26%	17,700 $249,000
Q2 2023 Aug 14, 2023	BUY	$17.0 - $21.58 $161,500 - $205,009	9,500 Added 500.0%	11,400 $215,000
Q4 2022 Feb 14, 2023	SELL	$16.0 - $25.45 $515,200 - $819,490	-32,200 Reduced 94.43%	1,900 $34,000
Q3 2022 Nov 14, 2022	SELL	$15.9 - $29.56 $518,340 - $963,656	-32,600 Reduced 48.88%	34,100 $611,000

6.5M

100

1.6K

Ticker XOMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,450,800
Market Cap $345M
Description
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolog...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.